Scholarlink

<p>Olaparib has low efficacy against BRCA-proficient ovarian cancer (OC); improving the efficacy of olaparib is expected to improve the prognosis of OC. In clinical practice, some BRCA-proficient cancers, similar to tumors with BRCA mutations, are sensitive to poly ADP‒ribose polymerase inhibitors (PARPis), a phenomenon known as BRCAness. This study aimed to identify BRCAness-inducing inhibitors that enhance olaparib antitumor efficacy in BRCA-proficient OC using patient-derived organoids (PDOs). We screened 28 inhibitors and evaluated their therapeutic value in combination with olaparib. Ultimately, an RPA70 inhibitor (HAMNO) and an ATR inhibitor (CGK733) significantly increased olaparib toxicity without causing major organ damage in mice. Mechanistically, HAMNO inhibits RPA70 binding to single-strand DNA (ssDNA) and hinders the recruitment of RAD51 at DNA double-strand breaks (DSBs), impairing homologous recombination repair (HRR). CGK733 induced BRCAness by blocking ATR function. Furthermore, the combination therapy with Olaparib was highly effective at inducing G2 phase arrest and inhibiting HRR. In addition, high RPA70 and ATR expression was found to indicate a poor prognosis in OC patients according to data from the Kaplan–Meier plotter database and clinical data from our center. In conclusion, our work provides an innovative approach for improving the therapeutic effect of olaparib on BRCA-proficient OC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HAMNO and CGK733 as BRCAness-driven candidates exhibit synthetic lethality with olaparib in BRCA-proficient ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Yashuang Zhang,
  • Xun Xu,
  • Jiangnan Qiu,
  • Meichen Wen,
  • Shuyi Zhang,
  • Huangyang Meng,
  • Lin Zhang,
  • Yi Jiang,
  • Wenjun Cheng

摘要

Olaparib has low efficacy against BRCA-proficient ovarian cancer (OC); improving the efficacy of olaparib is expected to improve the prognosis of OC. In clinical practice, some BRCA-proficient cancers, similar to tumors with BRCA mutations, are sensitive to poly ADP‒ribose polymerase inhibitors (PARPis), a phenomenon known as BRCAness. This study aimed to identify BRCAness-inducing inhibitors that enhance olaparib antitumor efficacy in BRCA-proficient OC using patient-derived organoids (PDOs). We screened 28 inhibitors and evaluated their therapeutic value in combination with olaparib. Ultimately, an RPA70 inhibitor (HAMNO) and an ATR inhibitor (CGK733) significantly increased olaparib toxicity without causing major organ damage in mice. Mechanistically, HAMNO inhibits RPA70 binding to single-strand DNA (ssDNA) and hinders the recruitment of RAD51 at DNA double-strand breaks (DSBs), impairing homologous recombination repair (HRR). CGK733 induced BRCAness by blocking ATR function. Furthermore, the combination therapy with Olaparib was highly effective at inducing G2 phase arrest and inhibiting HRR. In addition, high RPA70 and ATR expression was found to indicate a poor prognosis in OC patients according to data from the Kaplan–Meier plotter database and clinical data from our center. In conclusion, our work provides an innovative approach for improving the therapeutic effect of olaparib on BRCA-proficient OC.